Clinical Trial Update: Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating VELCADE (bortezomib) and Rituxan (rituximab) as front-line therapy for low-grade non-Hodgkin's lymphoma has completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Northwestern University | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-10-23